Compare PRE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | TLSI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Hong Kong | United States |
| Employees | 285 | 102 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 270.2M |
| IPO Year | N/A | N/A |
| Metric | PRE | TLSI |
|---|---|---|
| Price | $19.86 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $30.50 | $7.00 |
| AVG Volume (30 Days) | 277.9K | ★ 754.8K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $108.69 | $35.45 |
| Revenue Next Year | $58.68 | $37.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $2.20 |
| 52 Week High | $23.63 | $7.95 |
| Indicator | PRE | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 41.31 |
| Support Level | $12.92 | $2.20 |
| Resistance Level | $21.72 | $5.41 |
| Average True Range (ATR) | 1.66 | 0.30 |
| MACD | 0.45 | 0.03 |
| Stochastic Oscillator | 73.33 | 50.96 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.